Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)

Phase 3

Completed

• Conditions: Primary Immune Deficiency
• Interventions: Biological: IgPro20

• Registration Number: NCT00719680
• Lead Sponsor: CSL Behring

Brief Summary

The purpose of this study is to determine whether a long-term use of a new human immunoglobulin G with proline (IgPro) is safe and effective in the treatment of primary immunodeficiency.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-06
• Study First Submitted: 2008-07-21
• Study First Submitted QC: 2008-07-21
• Study First Posted: 2008-07-22
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Results First Submitted: 2012-11-27
• Status Verified: 2012-12
• Results First Submitted QC: 2012-12-20
• Results First Posted: 2013-01-25
• Last Update Submitted: 2014-03-05
• Last Update Posted: 2014-04-02

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• Subjects with primary humoral immunodeficiency who have participated in the study ZLB04_009CR (NCT00419341), namely with a diagnosis of Common Variable Immunodeficiency (CVID) as defined by PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies) or X-linked Agammaglobulinemia (XLA) as defined by PAGID and ESID
• Women of childbearing potential must be using and agree to continue using medically approved contraception and must have a negative pregnancy test at screening
• Written informed consent

Read More

Exclusion Criteria

• Ongoing serious bacterial infection at the time of screening
• Malignancies of lymphoid cells such as lymphocytic leukemia, Non-Hodgkin's lymphoma, and immunodeficiency with thymoma
• Hypoalbuminemia, protein-losing enteropathies, and any proteinuria (defined by total urine protein concentration > 0.2 g/L)
• Other significant medical conditions that could increase the risk to the patient
• Females who are pregnant, breast-feeding or planning a pregnancy during the course of the study
• A positive result at screening on any of the following viral markers: Human immunodeficiency virus (HIV), Hepatitis C virus (HCV) or Hepatitis B virus (HBV)
• Aspartate aminotransferase (ASAT) or Alanine aminotransferase (ALAT) concentration > 2.5 times Upper Normal Limit (UNL) at Completion Visit of study ZLB04_009CR (NCT00419341)
• Creatinine concentration > 1.5 times UNL at Completion Visit of study ZLB04_009CR (NCT00419341)
• Participation in a study with an investigational product other than IgPro20 within 3 months prior to enrollment
• Evidence of uncooperative attitude
• Any condition that is likely to interfere with evaluation of the study drug or satisfactory conduct of the trial
• Subjects who are employees at the investigational site, relatives or spouse of the investigator

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
IgPro20	IgPro20	The IgPro20 dose will be the same as in the previous pivotal study ZLB04_009CR (NCT00419341) infused subcutaneously weekly or twice a week (in the latter case, half of a weekly dose will be used)

Primary Outcome Measures

Name	Time	Method
Annualized Rate of Serious Bacterial Infection (Per-Protocol Efficacy Population)	For the duration of the study, up to approximately 104 weeks	The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.; Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.
Annualized Rate of Serious Bacterial Infection (Intention-to-Treat Population)	For the duration of the study, up to approximately 104 weeks	The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.; Acute serious bacterial infections included pneumonia, bacteremia/septicemia, osteomyelitis/septic arthritis, bacterial meningitis, and visceral abscess.

Secondary Outcome Measures

Name	Time	Method
Annualized Rate of Any Infection	For the duration of the study, up to approximately 104 weeks	The annualized rate was based on the total number of infections and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Rate of Temporally Associated AEs Within 24 or 72 Hours of an Infusion	Within 24 or 72 hours after each infusion	The rate of AEs was the number of AEs over the number of infusions administered.; AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
Trough Levels of Total Immunoglobulin G (IgG) Serum Concentrations	Before infusion at Weeks 1, 24, 48, 72, and 96	Mean of individual median total IgG trough concentration.
Number of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection	For the duration of the study, up to approximately 104 weeks
Annualized Rate of Days Out of Work / School / Kindergarten / Day Care or Inability to Perform Normal Activities Due to Infection	For the duration of the study, up to approximately 104 weeks	The annualized rate was based on the total number of days out of work / school / kindergarten / day care or inability to perform normal activities due to infection, and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Number of Days of Hospitalization Due to Infection	For the duration of the study, up to approximately 104 weeks
Annualized Rate of Hospitalization Due to Infection	For the duration of the study, up to approximately 104 weeks	The annualized rate was based on the total number of days of hospitalization due to infection and the total number of subject study days for all subjects in the specified analysis population and adjusted to 365 days.
Use of Antibiotics for Infection Prophylaxis and Treatment	For the duration of the study, up to approximately 104 weeks	Annualized rate of days with antibiotics for infection prophylaxis and treatment.
Rate of All AEs by Relatedness and Severity	For the duration of the study, up to approximately 104 weeks	The rate of AEs was the number of AEs over the number of infusions administered.; At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.; Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Relatedness and Severity of All AEs (Percentage of Total AEs)	For the duration of the study, up to approximately 104 weeks	At least possibly related AEs included possibly related AEs, probably related AEs, and related AEs.; Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Number of Subjects With Any Temporally Associated Adverse Event (AE) Within 24 or 72 Hours After an Infusion	Within 24 or 72 hours after each infusion	AEs were considered temporally associated if they occurred between the start of infusion and within 24 or 72 hours after the end of infusion.
Number of Subjects Reporting Mild, Moderate, or Severe Local AEs	For the duration of the study, up to approximately 104 weeks	In addition to the standard MedDRA System Organ Class (SOC) AE assignments, the category of 'local reactions' was defined to provide the possibility for a combined analysis of local reactions and included AEs of infusion site oedema, infusion site reaction, injection site pain, injection site rash, and injection site reaction.; Mild AE: Did not interfere with routine activities; Moderate AE: Interfered somewhat with routine activities; Severe AE: Impossible to perform routine activities.
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Vital Signs	At weeks 1, 12, 24, 36, 48, 60, 72, 84, and 96	Vital signs included blood pressure (systolic and diastolic), heart rate, and body temperature.
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Routine Laboratory Parameters	At Week 1, and study completion (approximately 104 weeks)	Routine laboratory parameters included hematology, blood chemistry, and urinalysis parameters.
Number of Subjects With Clinically Significant Changes From Baseline to the Completion Visit in Viral Safety Markers	At Week 1, and study completion (approximately 104 weeks)	Viral safety markers included human immunodeficiency virus (HIV)-1, HIV-2, hepatitis A virus (HAV), HBV, HCV, and parvovirus B19.

Trial Locations

Locations (1)

Contact CSL Behring for facility details; 🇺🇸 Dallas, Texas, United States